Cancer in Austria

IARC estimates 46,684 new cancer cases and 22,559 cancer deaths in Austria in 2024; the commonest new cancers are prostate, breast and trachea, bronchus and lung. This page is assembled automatically from OnCo's data: 482 trials with a site there, 5 institutions, 5 companies and 9 people, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

46,684

all cancers

Deaths

22,559

all cancers

Incidence rate

237.4

per 100,000, age-standardised

Mortality rate

85.8

per 100,000, age-standardised

Cumulative risk

24.0%

of a cancer by age 74

Population

9,120,818

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Prostate	6,661	66.0	Prostate cancer
Breast	5,623	60.4	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Trachea, bronchus and lung	5,056	24.0	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	4,240	18.9	Colorectal cancer
Non-Hodgkin lymphoma	2,690	13.1	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Melanoma of skin	2,211	11.5	Melanoma
Pancreas	2,107	8.4	Pancreatic ductal adenocarcinoma
Bladder	1,702	7.0	Bladder & urothelial cancer
Kidney	1,361	7.1	Renal cell carcinoma
Leukaemia	1,190	6.9	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	4,197	17.6	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	2,233	8.0	Colorectal cancer
Pancreas	2,069	7.9	Pancreatic ductal adenocarcinoma
Breast	1,781	13.2	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Prostate	1,570	10.5	Prostate cancer
Leukaemia	936	3.3	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Bladder	901	2.7	Bladder & urothelial cancer
Liver and intrahepatic bile ducts	869	3.4	Hepatocellular carcinoma
Non-Hodgkin lymphoma	742	2.4	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Stomach	736	2.8	Gastric & gastro-oesophageal junction cancer

Incidence: method 1, trends in national rates projected to 2024.
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Austria”, in Western Europe (Europe), Very High HDI, high income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

482 trials in OnCo · 124 recruiting overall

482 trials

Trial			Lead sponsor
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis NCT04910685	Phase 2/3	Recruiting	Blueprint Medicines Corporation	88	2026-10-07
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) NCT07190248	Phase 3	Recruiting	Merck Sharp & Dohme LLC	219	2026-10-07
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) NCT06345729	Phase 3	Recruiting	Merck Sharp & Dohme LLC	241	2026-10-07
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer NCT06119581	Phase 3	Recruiting	Eli Lilly and Company	416	2026-10-07
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa NCT06091865	Phase 3	Recruiting	Regeneron Pharmaceuticals	194	2026-10-07
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, NCT06820463	Phase 2	Recruiting	AbbVie	75	2026-10-07
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participant NCT06149286	Phase 3	Recruiting	Regeneron Pharmaceuticals	171	2026-10-07
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati NCT07195695	Phase 3	Recruiting	Boehringer Ingelheim	202	2026-10-07
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb NCT03486873	Phase 3	Recruiting	Merck Sharp & Dohme LLC	782	2026-10-07
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer NCT06890598	Phase 3	Recruiting	Eli Lilly and Company	366	2026-10-07
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) NCT06925737	Phase 3	Recruiting	Merck Sharp & Dohme LLC	298	2026-10-06
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc NCT07216703	Phase 3	Recruiting	Merck Sharp & Dohme LLC	180	2026-10-06
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) NCT07318558	Phase 3	Recruiting	Merck Sharp & Dohme LLC	165	2026-10-06
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan NCT06952504	Phase 3	Recruiting	Merck Sharp & Dohme LLC	265	2026-10-06
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl NCT06824467	Phase 3	Recruiting	Merck Sharp & Dohme LLC	197	2026-10-06
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy NCT06091254	Phase 3	Recruiting	Regeneron Pharmaceuticals	190	2026-10-06
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC NCT06216301	Phase 3	Recruiting	NovoCure GmbH	104	2026-10-06
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287 NCT06422143	Phase 3	Recruiting	Merck Sharp & Dohme LLC	216	2026-10-06
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive NCT07413939	Phase 2/3	Recruiting	Hoffmann-La Roche	206	2026-10-06
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) NCT06393374	Phase 3	Recruiting	Merck Sharp & Dohme LLC	314	2026-10-06
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma NCT06697301	Phase 2/3	Recruiting	Eikon Therapeutics	127	2026-10-06
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) NCT06136624	Phase 3	Recruiting	Merck Sharp & Dohme LLC	288	2026-10-06
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07155187	Phase 2/3	Recruiting	AbbVie	117	2026-10-05
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521	Phase 3	Recruiting	Relay Therapeutics, Inc.	243	2026-10-05
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM NCT05902169	Phase 3	Recruiting	CarThera	56	2026-10-05
TeliMET NSCLC-01 NCT04928846	Phase 3	Recruiting	AbbVie	317	2026-10-05
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) NCT07581002	Phase 2/3	Recruiting	AbbVie	36	2026-10-02
FORTIFI-HN01 NCT06788990	Phase 2/3	Recruiting	Bicara Therapeutics	231	2026-10-02
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma NCT07491445	Phase 3	Recruiting	Revolution Medicines, Inc.	82	2026-10-02
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re NCT05519085	Phase 3	Recruiting	Celgene	266	2026-09-30

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Austria, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Austria is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

5 institutions

BBMRI-ERIC (Biobanking and BioMolecular resources Research Infrastructure)Comprehensive Cancer Center Vienna, Medical University of Vienna / AKH European Association of Nuclear Medicine International Atomic Energy Agency: Rays of Hope St. Anna Children's Hospital and Children's Cancer Research Institute (CCRI)

5 companies

AOP Health Austrian Breast & Colorectal Cancer Study Group Hookipa Pharma pharma&Proxygen

9 people

People whose main affiliation in OnCo is an institution or company in Austria.

Christian Singer Gerald W. Prager Michael Gnant Nicole Concin Paola Anna Erba Rafael Mariano Grossi Rupert Bartsch Ruth Ladenstein Shahrokh F. Shariat

Approvals

Austria is an EU member state, so an EU centralised authorisation covers it: 309 products in OnCo carry a sourced EU row that is approved or conditional. See the approvals by region matrix. National procedures and reimbursement are not recorded.

From the country research ranking

Research funders: FWF; Austrian Cancer Aid.
Named in the ranking: MedAustron ion therapy.

From the country ranking's hand-curated row; follow its source before relying on a figure.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Austria's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Austria, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines agency's own procedures, beyond EU centralised authorisations.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Austria's own sources.

A deep dive for Austria is ranked 34 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today; Austria fact sheet.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/at.json; every country: /api/v1/countries.json.